LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Abivax SA Sponsored ADR today and set a price target of $45.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky has given his Buy rating due to a combination of factors that highlight the potential of Abivax’s obefazimod in treating ulcerative colitis (UC). The upcoming Phase 3 readout is highly anticipated, as obefazimod offers several distinguishing features that could significantly impact the market. These include its oral delivery method, a novel mechanism of action, and the potential to effectively treat late-line refractory patients, addressing an unmet need in the UC treatment landscape.
Moreover, obefazimod has demonstrated a favorable safety profile, which is crucial for its acceptance as an inflammatory bowel disease (IBD) medication. The Phase 2 maintenance data have been particularly promising, and if the Phase 3 induction data validate these results, it could pave the way for regulatory filing and potential approval. The market’s current landscape shows that most approved UC treatments have limitations, and obefazimod’s unique attributes could position it as a strong contender, justifying the Buy rating.
In another report released on July 3, Leerink Partners also reiterated a Buy rating on the stock with a $20.00 price target.